Quest Diagnostics Capital Expenditures (CapEx) Growth & History (DGX)
Quest Diagnostics's capital expenditures (capex) was $527.0M for fiscal 2025.
View full Quest Diagnostics company overviewQuest Diagnostics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $527.0M | $102.0M | +24.00% |
| 2024 | 2024-12-31 | $425.0M | $17.0M | +4.17% |
| 2023 | 2023-12-31 | $408.0M | $4.0M | +0.99% |
| 2022 | 2022-12-31 | $404.0M | $1.0M | +0.25% |
| 2021 | 2021-12-31 | $403.0M | −$15.0M | −3.59% |
| 2020 | 2020-12-31 | $418.0M | $18.0M | +4.50% |
| 2019 | 2019-12-31 | $400.0M | $17.0M | +4.44% |
| 2018 | 2018-12-31 | $383.0M | $131.0M | +51.98% |
| 2017 | 2017-12-31 | $252.0M | −$41.0M | −13.99% |
| 2016 | 2016-12-31 | $293.0M | $30.0M | +11.41% |
| 2015 | 2015-12-31 | $263.0M | −$45.0M | −14.61% |
| 2014 | 2014-12-31 | $308.0M | $77.0M | +33.33% |
| 2013 | 2013-12-31 | $231.0M | $49.0M | +26.92% |
| 2012 | 2012-12-31 | $182.0M | $21.0M | +13.04% |
| 2011 | 2011-12-31 | $161.0M | −$44.4M | −21.62% |
| 2010 | 2010-12-31 | $205.4M | $38.5M | +23.05% |
| 2009 | 2009-12-31 | $166.9M | −$45.8M | −21.51% |
| 2008 | 2008-12-31 | $212.7M | −$6.4M | −2.93% |
| 2007 | 2007-12-31 | $219.1M | — | — |
Quest Diagnostics quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $138.0M | $30.0M | +27.78% |
| Q1 2026 | 2026-03-31 | $114.0M | −$3.0M | −2.56% |
| Q4 2025 | 2025-12-31 | $158.0M | $35.0M | +28.46% |
| Q3 2025 | 2025-09-30 | $144.0M | $38.0M | +35.85% |
| Q2 2025 | 2025-06-30 | $108.0M | $16.0M | +17.39% |
| Q1 2025 | 2025-03-31 | $117.0M | $13.0M | +12.50% |
| Q4 2024 | 2024-12-31 | $123.0M | $51.0M | +70.83% |
| Q3 2024 | 2024-09-30 | $106.0M | $1.0M | +0.95% |
| Q2 2024 | 2024-06-30 | $92.0M | −$12.0M | −11.54% |
| Q1 2024 | 2024-03-31 | $104.0M | −$23.0M | −18.11% |
| Q4 2023 | 2023-12-31 | $72.0M | −$75.0M | −51.02% |
| Q3 2023 | 2023-09-30 | $105.0M | −$13.0M | −11.02% |
| Q2 2023 | 2023-06-30 | $104.0M | $28.0M | +36.84% |
| Q1 2023 | 2023-03-31 | $127.0M | $64.0M | +101.59% |
| Q4 2022 | 2022-12-31 | $147.0M | $3.0M | +2.08% |
| Q3 2022 | 2022-09-30 | $118.0M | $29.0M | +32.58% |
| Q2 2022 | 2022-06-30 | $76.0M | −$8.0M | −9.52% |
| Q1 2022 | 2022-03-31 | $63.0M | −$23.0M | −26.74% |
| Q4 2021 | 2021-12-31 | $144.0M | −$18.0M | −11.11% |
| Q3 2021 | 2021-09-30 | $89.0M | −$2.0M | −2.20% |
| Q2 2021 | 2021-06-30 | $84.0M | $2.0M | +2.44% |
| Q1 2021 | 2021-03-31 | $86.0M | $3.0M | +3.61% |
| Q4 2020 | 2020-12-31 | $162.0M | −$10.0M | −5.81% |
| Q3 2020 | 2020-09-30 | $91.0M | −$5.0M | −5.21% |
| Q2 2020 | 2020-06-30 | $82.0M | −$3.0M | −3.53% |
| Q1 2020 | 2020-03-31 | $83.0M | $36.0M | +76.60% |
| Q4 2019 | 2019-12-31 | $172.0M | $21.0M | +13.91% |
| Q3 2019 | 2019-09-30 | $96.0M | $15.0M | +18.52% |
| Q2 2019 | 2019-06-30 | $85.0M | $7.0M | +8.97% |
| Q1 2019 | 2019-03-31 | $47.0M | −$26.0M | −35.62% |
| Q4 2018 | 2018-12-31 | $151.0M | $69.0M | +84.15% |
| Q3 2018 | 2018-09-30 | $81.0M | $18.0M | +28.57% |
| Q2 2018 | 2018-06-30 | $78.0M | $13.0M | +20.00% |
| Q1 2018 | 2018-03-31 | $73.0M | $31.0M | +73.81% |
| Q4 2017 | 2017-12-31 | $82.0M | −$46.0M | −35.94% |
| Q3 2017 | 2017-09-30 | $63.0M | $2.0M | +3.28% |
| Q2 2017 | 2017-06-30 | $65.0M | $8.0M | +14.04% |
| Q1 2017 | 2017-03-31 | $42.0M | −$5.0M | −10.64% |
| Q4 2016 | 2016-12-31 | $128.0M | $34.0M | +36.17% |
| Q3 2016 | 2016-09-30 | $61.0M | $9.0M | +17.31% |
| Q2 2016 | 2016-06-30 | $57.0M | −$4.0M | −6.56% |
| Q1 2016 | 2016-03-31 | $47.0M | −$9.0M | −16.07% |
| Q4 2015 | 2015-12-31 | $94.0M | $5.0M | +5.62% |
| Q3 2015 | 2015-09-30 | $52.0M | −$50.0M | −49.02% |
| Q2 2015 | 2015-06-30 | $61.0M | $12.0M | +24.49% |
| Q1 2015 | 2015-03-31 | $56.0M | −$12.0M | −17.65% |
| Q4 2014 | 2014-12-31 | $89.0M | $13.0M | +17.11% |
| Q3 2014 | 2014-09-30 | $102.0M | $52.0M | +104.00% |
| Q2 2014 | 2014-06-30 | $49.0M | −$7.0M | −12.50% |
| Q1 2014 | 2014-03-31 | $68.0M | $19.0M | +38.78% |
| Q4 2013 | 2013-12-31 | $76.0M | $16.3M | +27.34% |
| Q3 2013 | 2013-09-30 | $50.0M | $5.1M | +11.33% |
| Q2 2013 | 2013-06-30 | $56.0M | $8.6M | +18.12% |
| Q1 2013 | 2013-03-31 | $49.0M | $19.0M | +63.34% |
| Q4 2012 | 2012-12-31 | $59.7M | $16.6M | +38.41% |
| Q3 2012 | 2012-09-30 | $44.9M | $5.7M | +14.41% |
| Q2 2012 | 2012-06-30 | $47.4M | $7.8M | +19.62% |
| Q1 2012 | 2012-03-31 | $30.0M | −$9.0M | −23.06% |
| Q4 2011 | 2011-12-31 | $43.1M | −$26.0M | −37.60% |
| Q3 2011 | 2011-09-30 | $39.3M | −$8.2M | −17.26% |
| Q2 2011 | 2011-06-30 | $39.6M | −$9.5M | −19.26% |
| Q1 2011 | 2011-03-31 | $39.0M | −$772,000 | −1.94% |
| Q4 2010 | 2010-12-31 | $69.1M | $19.2M | +38.51% |
| Q3 2010 | 2010-09-30 | $47.4M | $6.4M | +15.61% |
| Q2 2010 | 2010-06-30 | $49.1M | $12.7M | +34.90% |
| Q1 2010 | 2010-03-31 | $39.8M | $153,000 | +0.39% |
| Q4 2009 | 2009-12-31 | $49.9M | — | — |
| Q3 2009 | 2009-09-30 | $41.0M | — | — |
| Q2 2009 | 2009-06-30 | $36.4M | — | — |
| Q1 2009 | 2009-03-31 | $39.6M | — | — |
Quest Diagnostics capital expenditures (capex) trends
Over the last five fiscal years, Quest Diagnostics's capital expenditures (capex) increased from $418.0M to $527.0M, a change of $109.0M. The latest reported quarter, Q2 2026, shows $138.0M.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Quest Diagnostics source filings ↗